Takeda Pharmaceutical Company L (TAK) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Multiple concerning factors at $15.55: Consecutive earnings misses (3); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived... Read more
Sell if holding. Multiple concerning factors at $15.55: Consecutive earnings misses (3); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Takeda Pharmaceutical Company L
Latest news
- NEWS Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation (NYSE:TAK) 2026-05-13 - Seeking Alp — Seeking Alpha neutral
- NEWS What's Going On With Takeda Stock Wednesday? - Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga — Benzinga neutral
- NEWS Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience By Investing.com - Investing.com India — Investing.com India positive
- NEWS Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO - Moomoo — Moomoo negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $15.55: Consecutive earnings misses (3); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.06. Score 5.1/10, moderate confidence.
Take-profit target: $17.35 (+10.2% upside). Prior stop was $15.06. Stop-loss: $15.06.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Consecutive earnings misses (3); Weak growth.
Takeda Pharmaceutical Company L trades at a P/E of 42.5 (forward 29.7). TrendMatrix value score: 7.0/10. Verdict: Sell.
19 analysts cover TAK with a consensus score of 3.9/5. Average price target: $20.
What does Takeda Pharmaceutical Company L do?Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.